Cambridge, United Kingdom
Dunad Therapeutics is a pioneering company in the Biotechnology and Pharmaceutical industries, founded in 2020 and headquartered in the United States. The company is driven by its slogan: "Tunable covalent chemistry with a deep understanding of disease biology to develop transformational medicines."
The startup's core strength lies in its proprietary chemistry platform which allows for the development of highly selective and durable medicines that target the fundamental drivers of diseases. This novel approach is poised to revolutionize the treatment landscape by offering more precise and long-lasting therapeutic options.
Dunad's promising trajectory is underscored by a successful $24.00M Series A investment secured on 01 November 2021. This round saw participation from notable investors such as BioGeneration Ventures, Epidarex Capital, and Amblyotech, indicating strong market confidence in the company's innovative approach and growth potential.
C4 Therapeutics, Inc.
